Affinity of vitamin E analogues for the ubiquinone complex II site correlates with their toxicity to cancer cells

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F11%3A00369496" target="_blank" >RIV/86652036:_____/11:00369496 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1002/mnfr.201100066" target="_blank" >http://dx.doi.org/10.1002/mnfr.201100066</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/mnfr.201100066" target="_blank" >10.1002/mnfr.201100066</a>

Result language
angličtina
Original language name
Affinity of vitamin E analogues for the ubiquinone complex II site correlates with their toxicity to cancer cells
Original language description
Vitamin E (VE) analogues, epitomised by the prototypic alpha-tocopheryl succinate (alpha-TOS), are potent anti-cancer agents. alpha-TOS has recently been shown to trigger apoptosis by targeting the ubiquinone (UbQ) binding site(s) of the mitochondrial complex II (CII) and to cause excessive production of reactive oxygen species. We have modelled, using two approaches, a range of VE analogues into the proximal UbQ (Q(P)) binding site of CII. This study reveals that in both cases, the calculated interaction energies of individual VE analogues correlate (R(2) value >0.8) with their toxicity to cancer cells. These data further support the UbQ site(s) of CII as an important target determining the anti-cancer activity of VE analogues as well as other emerging anti-cancer drugs.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CE - Biochemistry
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)